HK1055256A1 - A bioavailable dosage form of loratadine. - Google Patents

A bioavailable dosage form of loratadine.

Info

Publication number
HK1055256A1
HK1055256A1 HK03107616A HK03107616A HK1055256A1 HK 1055256 A1 HK1055256 A1 HK 1055256A1 HK 03107616 A HK03107616 A HK 03107616A HK 03107616 A HK03107616 A HK 03107616A HK 1055256 A1 HK1055256 A1 HK 1055256A1
Authority
HK
Hong Kong
Prior art keywords
loratadine
dosage form
bioavailable dosage
bioavailable
particle size
Prior art date
Application number
HK03107616A
Other languages
English (en)
Inventor
Pananchukunath Manoj Kumar
Dinsheet Gupta
Rajiv Malik
Original Assignee
Ranbaxylaboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11097068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1055256(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ranbaxylaboratories Ltd filed Critical Ranbaxylaboratories Ltd
Publication of HK1055256A1 publication Critical patent/HK1055256A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
HK03107616A 2000-07-17 2003-10-21 A bioavailable dosage form of loratadine. HK1055256A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN651DE2000 IN192160B (no) 2000-07-17 2000-07-17
PCT/IB2001/001098 WO2002005816A1 (en) 2000-07-17 2001-06-21 A bioavailable dosage form of loratadine

Publications (1)

Publication Number Publication Date
HK1055256A1 true HK1055256A1 (en) 2004-01-02

Family

ID=11097068

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03107616A HK1055256A1 (en) 2000-07-17 2003-10-21 A bioavailable dosage form of loratadine.

Country Status (13)

Country Link
US (1) US20020035119A1 (no)
EP (1) EP1303276B1 (no)
AT (1) ATE278404T1 (no)
AU (1) AU2001274381A1 (no)
BR (1) BR0112597A (no)
DE (1) DE60106266T2 (no)
DK (1) DK1303276T3 (no)
ES (1) ES2230325T3 (no)
HK (1) HK1055256A1 (no)
IN (1) IN192160B (no)
PT (1) PT1303276E (no)
WO (1) WO2002005816A1 (no)
ZA (1) ZA200300439B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241997B2 (en) 2003-06-13 2016-01-26 Idh Holding Aps Treatment of symptoms associated with bacterial vaginosis
JP3881640B2 (ja) * 2003-08-08 2007-02-14 塩野義製薬株式会社 ロラタジンを含むドライシロップ剤
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
CA2628716C (en) * 2005-11-10 2016-09-27 Alphapharm Pty Ltd Process to control particle size
US20100104636A1 (en) * 2006-12-21 2010-04-29 Panagiotis Keramidas Pharmaceutical Compound and Composition
EP2318350A4 (en) * 2008-07-25 2012-11-28 Alphapharm Pty Ltd ATOVAQUONE WITH PARTICLE DIAMETER (D90) VARIANT FROM MORE THAN 3 muM TO ABOUT 10 muM

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980778A (en) * 1973-10-25 1976-09-14 The Upjohn Company Anti-inflammatory steroid
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
IL131317A (en) * 1999-08-09 2006-08-01 Cts Chemical Ind Ltd Binder for pharmaceutical compositions

Also Published As

Publication number Publication date
EP1303276A1 (en) 2003-04-23
WO2002005816A1 (en) 2002-01-24
DE60106266T2 (de) 2006-02-23
DK1303276T3 (da) 2005-02-07
DE60106266D1 (de) 2004-11-11
PT1303276E (pt) 2005-02-28
ES2230325T3 (es) 2005-05-01
ATE278404T1 (de) 2004-10-15
ZA200300439B (en) 2004-02-10
US20020035119A1 (en) 2002-03-21
BR0112597A (pt) 2003-08-12
EP1303276B1 (en) 2004-10-06
IN192160B (no) 2004-02-28
AU2001274381A1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
HUP0002316A3 (en) Flash-melt oral dosage formulation
EP1365354A4 (en) COUNTING AND FEEDING DEVICE FOR A SMALL ARTICLE
HUP0203204A3 (en) Oral dosage forms
AU7616001A (en) Probiotic recolonisation therapy
PL364621A1 (en) Nicotine-containing oral dosage form
GB9929613D0 (en) Manufacture of semiconductor material and devices using that material
IL154404A0 (en) Oral solid dose vaccine
AU9272401A (en) Cripto mutant and uses thereof
IL154012A0 (en) Hydrogel-driven drug dosage form
CA2388671A1 (en) Magnetic therapeutic mouth piece
HUP0500638A3 (en) Flashmelt oral dosage formulation
HK1055256A1 (en) A bioavailable dosage form of loratadine.
EP1164640A4 (en) SEMICONDUCTOR DEVICE AND METHOD FOR MANUFACTURING THE SAME
GB0025611D0 (en) Tablet inserters
GB0130923D0 (en) Semiconductor device manufacture and design
GB0023654D0 (en) Device for administering doses of particulate material
HUP0301433A3 (en) Use of antiprogestins for producung pharmaceutical compositions for induction of apoptosis in a cell
EP1357898A4 (en) ORAL DOSAGE FORM WITH ENHANCED REGULATED RELEASE
EG22762A (en) Receptacle and receptacle device
GB0030587D0 (en) Oral administration of beneficial substances
HK1047232A1 (zh) 口服劑型
IL149461A0 (en) Semiconductor nanocrystalline materials and their uses
GB9925069D0 (en) Oral dosage form
PL341178A1 (en) Oral pharmaceutical dosage forms
IL160195A0 (en) Oral dosage form comprising a therapeutic agent and an adverse-effect agent

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080621